Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.71 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31048928 | 1.00 | KEAP1 (0.71) | KEAP1NFE2L2ALDH1A1ALOX15CASP1 | |
| SCHEMBL29744459 | 0.83 | KEAP1 (1.00) | KEAP1NFE2L2ALDH1A1CASP1CTNNB1 | |
| SCHEMBL113812 | 0.83 | KEAP1 (1.00) | KEAP1NFE2L2ALDH1A1CASP1CTNNB1 | |
| Hydrochloric Acid SCHEMBL919985 | 0.82 | KEAP1 (0.96) | KEAP1NFE2L2ALDH1A1CASP1CTNNB1 | |
| SCHEMBL30474526 | 0.82 | KEAP1 (0.69) | KEAP1NFE2L2CASP1POLB | |
| SCHEMBL166218 | 0.82 | KEAP1 (0.69) | KEAP1NFE2L2CASP1POLB | |
| SCHEMBL10518552 | 0.82 | KEAP1 (0.69) | KEAP1NFE2L2ALDH1A1CASP1CTNNB1 | |
| SCHEMBL5871710 | 0.80 | KEAP1 (0.61) | KEAP1NFE2L2CASP1CTNNB1TCF7L2 | |
| SCHEMBL20788868 | 0.80 | KEAP1 (0.61) | KEAP1NFE2L2ALDH1A1CASP1CTNNB1 | |
| SCHEMBL31048876 | 0.79 | KEAP1 (0.65) | KEAP1NFE2L2CTNNB1TCF7L2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117732272-A | Mixed matrix membrane with high stability, preparation method and application | 江苏大学 | 2024-03-22 | — | — | CN | claimed |
| CN-115703648-A | Modified zinc oxide, preparation method thereof and light-emitting diode | TCL科技集团股份有限公司 | 2023-02-17 | — | — | CN | claimed |
| EP-0187376-A2 | 6,7-Disubstituted 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids | BAYER AG (DE) | 1986-07-16 | — | — | EP | claimed |
| US-20260132127-A1 | NOVEL SPIRO COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-05-14 | — | — | US | disclosed |
| EP-4716531-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | Board of Regents, The University of Texas System (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070925-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | UNIV TEXAS (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260022118-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | UNIV TEXAS (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4626427-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND A BCL-2 INHIBITOR | Janssen Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4626426-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND AT LEAST ONE OTHER THERAPEUTIC AGENT | JANSSEN Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| US-20250302840-A1 | COMBINATION THERAPIES | JANSSEN-CILAG (FR) | 2025-10-02 | — | — | US | disclosed |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| US-4840954-A | BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-20 | — | — | US | disclosed |
| EP-0302372-A1 | Naphthyridine antianaerobic compounds | ABBOTT LABORATORIES (US) | 1989-02-08 | — | — | EP | disclosed |
| US-4738968-A | 1,8-naphthyridine derivatives useful as anti-bacterial agents | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1988-04-19 | — | — | US | disclosed |
| EP-0132845-B1 | NOVEL 1,8-NAPHTHYRIDINE DERIVATIVES, AND PROCESS FOR PREPARATION THEREOF | Dainippon Pharmaceutical Co., Ltd. (JP) | 1988-04-13 | — | — | EP | disclosed |
| US-4649144-A | Antibacterial 7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid derivatives | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1987-03-10 | — | — | US | disclosed |
| EP-0191451-A1 | Novel 1,8-naphthyridine derivatives and processes for preparation thereof | Dainippon Pharmaceutical Co., Ltd. (JP) | 1986-08-20 | — | — | EP | disclosed |
| EP-0187376-A2 | 6,7-Disubstituted 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids | BAYER AG (DE) | 1986-07-16 | — | — | EP | disclosed |
| EP-0160578-A1 | 1,8-Naphthyridine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1985-11-06 | — | — | EP | disclosed |
| EP-0132845-A2 | Novel 1,8-Naphthyridine derivatives, and process for preparation thereof | Dainippon Pharmaceutical Co., Ltd. (JP) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070925-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | NRAS, KRAS, HRAS | KEAP1 88/4885NFE2L2 1005/4885ALDH1A1 4329/4885 |
| US-20250302840-A1 | COMBINATION THERAPIES | MEN1, MLLT1, BMI1 | KEAP1 1091/4885NFE2L2 1209/4885ALDH1A1 3293/4885 |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | KEAP1 47/4885NFE2L2 423/4885ALDH1A1 2204/4885 |
| US-20260132127-A1 | NOVEL SPIRO COMPOUND | TRHR, NR3C2, THRB | KEAP1 911/4885NFE2L2 1705/4885ALDH1A1 1063/4885 |
| US-20260022118-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | NRAS, KRAS, HRAS | KEAP1 76/4885NFE2L2 1271/4885ALDH1A1 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.